Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00578630 · ClinicalTrials.gov registry record
Interindividual Genetic Variability as a Determinant of Chemotherapy Toxicity and Response in Pediatric Bone Marrow Transplantation Patients
A clinical trial, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- 128
- Enrollment target
NCT00578630: Completed study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00578630 is a clinical trial that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 128 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00578630 has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- 128 participants
- Enrollment target
Study Summary
The purpose of this study is to develop tests that will allow us to determine who will react differently to the drugs used to treat cancer. We also want to see who will react differently with preparing for a bone marrow transplant.
Interventions
- OTHER buccal swabs and obtaining peripheral blood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 128 participants |
| Start Date | 2003-10-14 |
| Est. Completion | 2018-11 |
What the finished NCT00578630 record still lists
NCT00578630 is an observational study that tracks outcomes without assigning an intervention. The registered 128 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which buccal swabs and obtaining peripheral blood is the first listed.
NCT00578630 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00578630 about?
NCT00578630 is a clinical study titled "Interindividual Genetic Variability as a Determinant of Chemotherapy Toxicity and Response in Pediatric Bone Marrow Transplantation Patients". The purpose of this study is to develop tests that will allow us to determine who will react differently to the drugs used to treat cancer. We also want to see who will react differently with preparing for a bone marrow transplant.
What is the current status of trial NCT00578630?
This trial is currently completed. The enrollment target is 128 participants. The study started on 2003-10-14. Estimated completion is 2018-11.
What interventions are being tested in trial NCT00578630?
The interventions under investigation include: buccal swabs and obtaining peripheral blood (OTHER).
Who is sponsoring clinical trial NCT00578630?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02870738 · 128 participants · Phase 2
Bladder Directed vs. Pelvic Floor Therapy in IC/BPS
- NCT03294460 · 128 participants · Phase 1
Nicotinic Receptor Genetic Variation and Alcohol Reward
- NCT04149977 · 128 participants · NA
Blood Flow Restriction Therapy in Lower Limb Extensor Injuries
- NCT04373057 · 128 participants · Phase 1
Prebiotic Galacto-oligosaccharide and Acute GVHD
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI